Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia

被引:210
作者
London, GM [1 ]
Marchais, SJ [1 ]
Guérin, AP [1 ]
Métivier, F [1 ]
机构
[1] Hop FH Manhes, Serv Hemodialyse, F-91712 Fleury Merogis, France
关键词
arterial stiffness; chronic kidney disease; hypercalcemia; hyperphosphatemia; vascular calcification;
D O I
10.1097/01.mnh.0000168336.67499.c0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Arterial calcification in chronic kidney disease (CKD) is associated with increased cardiovascular risk. The mechanisms responsible for arterial calcification include alterations of mineral metabolism and expression of mineral-regulating proteins. Recent findings Arterial calcification is similar to bone formation, involving differentiation of vascular smooth muscle cells (VSMCs) into phenotypically distinct osteoblast-like cells. Elevated phosphate and/or calcium trigger a concentration-dependent increase of calcium precipitates in VSMC in vitro. The calcification is initiated by VSMC release of membrane-bound matrix vesicles and formation of apoptotic bodies. The presence of serum prevents these changes, indicating the presence of calcification inhibitors. Arterial calcification occurs in two sites: the tunica intima and tunica media. Intimal calcification is a marker of atherosclerotic disease and is associated with arterial stenotic lesions. Medial calcification influences outcome by promoting arterial stiffening whose principal consequences are left-ventricular hypertrophy and altered coronary perfusion. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in CKD patients. Age, duration of dialysis, smoking and diabetes are risk factors for the development of arterial calcification in end-stage renal disease. Oversuppression of parathyroid hormone and low bone turnover potentiate the development of arterial calcification. Summary Arterial disease in CKD patients is characterized by extensive calcification. Evidence has accumulated pointing to the active and regulated nature of the calcification process. Elevated phosphate and calcium may stimulate sodium-dependent phosphate cotransport involving osteoblast-like changes in cellular gene expression. Arterial calcification is responsible for stiffening of the arteries with increased left-ventricular afterload and abnormal coronary perfusion as the principal clinical consequences.
引用
收藏
页码:525 / 531
页数:7
相关论文
共 101 条
  • [11] Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells
    Chen, NX
    O'Neill, KD
    Duan, D
    Moe, SM
    [J]. KIDNEY INTERNATIONAL, 2002, 62 (05) : 1724 - 1731
  • [12] Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure
    Chertow, GM
    Burke, SK
    Lazarus, JM
    Stenzel, KH
    Wombolt, D
    Goldberg, D
    Bonventre, JV
    Slatopolsky, E
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (01) : 66 - 71
  • [13] The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients
    Chertow, GM
    Raggi, P
    McCarthy, JT
    Schulman, G
    Silberzweig, J
    Kuhlik, A
    Goodman, WG
    Boulay, A
    Burke, SK
    Toto, RD
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2003, 23 (05) : 307 - 314
  • [14] Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
    Chertow, GM
    Burke, SK
    Raggi, P
    [J]. KIDNEY INTERNATIONAL, 2002, 62 (01) : 245 - 252
  • [15] Cozzolino M, 2001, J AM SOC NEPHROL, V12, P2511, DOI 10.1681/ASN.V12112511
  • [16] A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients
    D'Haese, PC
    Spasovski, GB
    Sikole, A
    Hutchison, A
    Freemont, TJ
    Sulkova, S
    Swanepoel, C
    Pejanovic, S
    Djukanovic, L
    Balducci, A
    Coen, G
    Sulowicz, W
    Ferreira, A
    Torres, A
    Curic, S
    Popovic, M
    Dimkovic, N
    De Broe, ME
    [J]. KIDNEY INTERNATIONAL, 2003, 63 : S73 - S78
  • [17] BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure
    Davies, MR
    Lund, RJ
    Hruska, KA
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (06): : 1559 - 1567
  • [18] Pathophysiological mechanisms of vascular calcification in end-stage renal disease
    Davies, MR
    Hruska, KA
    [J]. KIDNEY INTERNATIONAL, 2001, 60 (02) : 472 - 479
  • [19] Prognostic value of coronary calcification and angiographic stenoses in patients undergoing coronary angiography
    Detrano, R
    Hsiai, T
    Wang, SJ
    Puentes, G
    Fallavollita, J
    Shields, P
    Stanford, W
    Wolfkiel, C
    Georgiou, D
    Budoff, M
    Reed, J
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 27 (02) : 285 - 290
  • [20] The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
    Finkelstein, JS
    Hayes, A
    Hunzelman, JL
    Wyland, JJ
    Lee, H
    Neer, RM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) : 1216 - 1226